Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines

BMC Clinical Pharmacology

Ioannis Papasotiriou¹  Dimitrios Komiotis²  Joe Nester³  Dennis R Knocke³  Eleni Ioannou¹  Marina Chatziioannou¹  Maria Toloudi¹  Panagiotis Apostolou¹ 

[1] Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), Filotas, Florina, Greece;Department of Biochemistry & Biotechnology, University of Thessaly, Larisa, Greece;Nerium Biotechnology, Inc. San Antonio, Texas, USA

关键词: Methyl-tetrazolium dye;    Cancer cell lines;    Viability assays;    Cisplatin;    Anvirzel™;   

Others  :  860622
DOI  :  10.1186/2050-6511-14-18

 received in 2012-08-03, accepted in 2013-03-20,  发布年份 2013

【 摘 要 】

Background

Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. Anvirzel™ is an extract which has been demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine whether the combination of Cisplatin and Anvirzel™ has a synergistic effect against different types of cancer.

Materials and methods

To measure the efficacy of treatment with Cisplatin and Anvirzel™, methyl-tetrazolium dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements were performed in triplicates, three times, using different incubation times and different concentrations of the two formulations in combination or on their own. t-test was used for statistical analysis.

Results

In the majority of the cell lines tested, lower concentrations of Anvirzel™ induced a synergistic effect when combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of Anvirzel™/Cisplatin showed anti-proliferative effects against a wide range of tumours.

Conclusion

The results showed that the combination of Anvirzel™ and Cisplatin is more effective than monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided.

【 授权许可】

   
2013 Apostolou et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Sreenivasan YSA, Manna SK: Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 2003, 66:2223-2239.
• [2]Newman RA, Kondo Y, Yokoyama T: Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 2007, 6:354-364.
• [3]Raghavendra PB, Sreenivasan Y, Ramesh GT, Manna SK: Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. Apoptosis 2007, 12:307-1318.
• [4]Frese SF-SM, Andres AC, Miescher D, Zumkehr B, Schmid RA: Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006, 66:5867-5874.
• [5]Raghavendra PB, Sreenivasan Y, Manna SK: Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol Immunol 2007, 44:2292-2302.
• [6]Stenkvist B: Cardenolides and cancer. Anticancer Drugs 2001, 12:635-638.
• [7]Langford SD, Boor PJ: Oleander toxicity: an examination of human and animal toxic exposures. Toxicology 1996, 109:1-13.
• [8]Wang X, Plomley JB, Newman RA, Cisneros A: LC/MS/MS analyses of an oleander extract for cancer treatment. Anal Chem 2000, 72:3547-52.
• [9]Pathak S, Multani AS, Narayan S, Kumar V, Newman RA: Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 2000, 11:455-63.
• [10]McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA: Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000, 60:3807-3812.
• [11]Smith JA, Madden T, Vijjeswarapu M, Newman RA: Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 2001, 62:469-472.
• [12]Apostolou P, Toloudi M, Chatziioannou M, Papasotiriou I: Determination of efficacy of Anvirzel™ in 37 established cancer cell lines. International Pharmaceutical Industry 2011, 3:68-72.
• [13]Rosenberg B, VanCamp L, Trosko JE, Mansour VH: Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386.
• [14]Trzaska S: The top pharmaceuticals that changed the world. C&EN News 2005, 83:3.
• [15]Stordal B, Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59:696-699.
• [16]Chen XX, Lai MD, Zhang YL, Huang Q: Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. World J Gastroenterol 2002, 8:841-846.
• [17]Alshehri A, Beale P, Yu JQ, Huq F: Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines. Anticancer Res 2010, 30:4547-4553.
• [18]Apostolou P, Toloudi M, Chatziioannou M, Papasotiriou I: Studying the effect of Anvirzel™, Carboplatin and Docetaxel in NSCLC cell lines. Journal for Clinical Studies 2011, 3:32-34.
• [19]Liu Y, Peterson DA, Kimura H, Schubert D: Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 1997, 69:581-593.
• [20]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
• [21]Mickisch G, Fajta S, Keilhauer G, Schlick E, Tschada R, Alken P: Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT). Urol Res 1990, 18:131-136.
• [22]Sargent JM: The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results Cancer Res 2003, 161:13-25.
• [23]Twentyman PR, Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987, 56:279-285.
• [24]Ingle JDJ, Crouch SR: Spectrochemical Analysis. New Jersey: Prentice Hall; 1988.
• [25]Leporatti ML, Posocco E, Pavesi A: Some new therapeutic uses of several medicinal plants in the province of Terni (Umbria, Central Italy). J Ethnopharmacol 1985, 14:65-68.
• [26]Wolfred MM: The evaluation of the glycoside oleandrin, on the embryo chick heart. J Am Pharm Assoc Am Pharm Assoc 1949, 38:581-584.
• [27]Manna SK, Sah NK, Newman RA, Cisneros A, Aggarwal BB: Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res 2000, 60:3838-3847.
• [28]Chen JQ, Contreras RG, Wang R: Sodium/potassium ATPase (Na+, K + −ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs? Breast Cancer Res Treat 2006, 96:1-15.